Organogenesis (company)

Organogenesis (company). Organogenesis is a leading American regenerative medicine company focused on the development, manufacturing, and commercialization of product solutions for the advanced wound care and surgical and sports medicine markets. Founded in 1985, the company pioneered the first FDA-approved living cell-based therapies and has maintained a significant presence in the field of tissue engineering. Its commercial portfolio and robust research and development pipeline are built upon expertise in biomaterials and cell biology.

History

The company was founded in 1985 by entrepreneur and scientist Gary S. Jacob. Its early work was instrumental in advancing the field of tissue engineering, culminating in a landmark achievement in 1998 when its product Apligraf became the first living bilayered skin substitute to receive FDA approval for marketing in the United States. This approval for treating venous leg ulcers marked a significant milestone in regenerative medicine. In 2001, Organogenesis acquired the assets of Advanced Tissue Sciences, including the human fibroblast-derived dermal substitute Dermagraft, which was subsequently re-launched. The company underwent a significant corporate transition, becoming a publicly traded entity on the NASDAQ under the ticker "ORGO" in 2018 after a merger with Harvard Bioscience, Inc.. Throughout its history, Organogenesis has expanded its manufacturing capabilities at facilities in Canton, Massachusetts and Livermore, California.

Products and technologies

Organogenesis's commercial portfolio is segmented into advanced wound care and surgical and sports medicine. Its flagship advanced wound care products include Apligraf, a living cell-based product indicated for venous leg ulcers and diabetic foot ulcers, and Dermagraft, a cryopreserved human fibroblast-derived dermal substitute for diabetic foot ulcers. The portfolio also features the PuraPly family of antimicrobial xenogeneic collagen matrices, such as PuraPly AM and PuraPly XT. In surgical and sports medicine, the company offers the NuCel product line, which includes NuShield and Affinity, amniotic tissue-based allografts used in applications like tendon repair and soft tissue regeneration. These technologies leverage a combination of scaffold-based and cell therapy platforms.

Research and development

The company's research and development efforts are centered on expanding the applications of its core technology platforms and developing next-generation regenerative products. This work often involves clinical trials to secure new FDA clearances and expand indications for existing products. Research focuses on enhancing product formulations, improving delivery mechanisms, and exploring combinations of biologic scaffolds with cells or growth factors. Collaborations with key opinion leaders at academic medical centers and research institutions are a staple of its R&D strategy. The pipeline aims to address unmet needs in chronic wound healing, osteoarthritis, and various soft tissue reconstruction challenges.

Corporate affairs

Organogenesis is headquartered in Canton, Massachusetts, with additional operations and manufacturing in Livermore, California. The company is led by its founder, Gary S. Jacob, who has served as Chief Executive Officer since its inception. As a publicly traded company on the NASDAQ, it operates with a commercial model that includes a direct sales force targeting hospitals, wound care centers, and outpatient surgery centers across the United States. The corporate structure is designed to integrate manufacturing, quality assurance, and commercial distribution to support its portfolio of regulated medical devices and biologics.

Clinical impact and recognition

The clinical introduction of Apligraf and Dermagraft provided novel treatment options for complex, non-healing wounds that were previously difficult to manage, influencing standards of care in podiatry and wound care. The company's products have been incorporated into treatment guidelines from professional societies. Organogenesis has received numerous awards and recognitions for innovation, including accolades from Frost & Sullivan and being named to lists of fastest-growing companies. Its work has contributed significantly to the body of clinical evidence supporting the use of advanced therapeutics in regenerative medicine, with data published in peer-reviewed journals like the International Wound Journal and Wound Repair and Regeneration.

Category:Biotechnology companies of the United States Category:Companies based in Massachusetts Category:Regenerative medicine companies